Brief

The State Drug Alert for October 2024 highlights multiple Not of Standard Quality (NSQ) and misbranded drugs, indicating serious quality and compliance failures in various pharmaceutical products. The report underscores critical issues such as dissolution failures, sterility breaches, assay inconsistencies, and labeling violations, reinforcing the need for strict regulatory oversight and adherence to quality standards.

This content is restricted.

Highlights content goes here...

This content is restricted.

Central Drugs Standard Control Organization (CDSCO)

Quick Insight
RADA.AI
RADA.AI
Hello! I'm RADA.AI - Regulatory Analysis and Decision Assistance. Your Intelligent guide for compliance and decision-making. How can i assist you today?
Suggested

Form successfully submitted. One of our GRI rep will contact you shortly

Thanking You!

Enter your Email

Enter your registered username/email id.

Enter your Email

Enter your email id below to signup.
Individual Plan
$125 / month OR $1250 / year
Features
Best for: Researchers, Legal professionals, Academics
Enterprise Plan
Contact for Pricing
Features
Best for: Law Firms, Corporations, Government Bodies